These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 32841538)
1. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer. den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538 [TBL] [Abstract][Full Text] [Related]
2. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer. Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M Oncology; 2018; 95(5):281-287. PubMed ID: 30149394 [TBL] [Abstract][Full Text] [Related]
3. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy. Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486 [TBL] [Abstract][Full Text] [Related]
4. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Tamandl D; Paireder M; Asari R; Baltzer PA; Schoppmann SF; Ba-Ssalamah A Eur Radiol; 2016 May; 26(5):1359-67. PubMed ID: 26334504 [TBL] [Abstract][Full Text] [Related]
5. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514 [TBL] [Abstract][Full Text] [Related]
7. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Yip C; Goh V; Davies A; Gossage J; Mitchell-Hay R; Hynes O; Maisey N; Ross P; Gaya A; Landau DB; Cook GJ; Griffin N; Mason R Eur Radiol; 2014 May; 24(5):998-1005. PubMed ID: 24535076 [TBL] [Abstract][Full Text] [Related]
8. Cardiopulmonary exercise testing has greater prognostic value than sarcopenia in oesophago-gastric cancer patients undergoing neoadjuvant therapy and surgical resection. West MA; Baker WC; Rahman S; Munro A; Jack S; Grocott MP; Underwood TJ; Levett DZ; J Surg Oncol; 2021 Dec; 124(8):1306-1316. PubMed ID: 34463378 [TBL] [Abstract][Full Text] [Related]
9. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010 [TBL] [Abstract][Full Text] [Related]
10. Impact of Body Mass Index on Complications and Survival after Surgery for Esophageal and Gastro-Esophageal-Junction Cancer. Kruhlikava I; Kirkegård J; Mortensen FV; Kjær DW Scand J Surg; 2017 Dec; 106(4):305-310. PubMed ID: 28737095 [TBL] [Abstract][Full Text] [Related]
11. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation. Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646 [TBL] [Abstract][Full Text] [Related]
12. Clinical impact of skeletal muscle mass change during the neoadjuvant chemotherapy period in patients with gastric cancer: An ancillary study of JCOG1002. Sato R; Tokunaga M; Mizusawa J; Sato Y; Ito S; Takahari D; Sano T; Onaya H; Yoshikawa T; Boku N; Terashima M World J Surg; 2024 Jan; 48(1):163-174. PubMed ID: 38686798 [TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle loss in the postoperative acute phase after esophageal cancer surgery as a new prognostic factor. Maeda N; Shirakawa Y; Tanabe S; Sakurama K; Noma K; Fujiwara T World J Surg Oncol; 2020 Jun; 18(1):143. PubMed ID: 32591002 [TBL] [Abstract][Full Text] [Related]
14. Myosteatosis predicts higher complications and reduced overall survival following radical oesophageal and gastric cancer surgery. Murnane LC; Forsyth AK; Koukounaras J; Pilgrim CH; Shaw K; Brown WA; Mourtzakis M; Tierney AC; Burton PR Eur J Surg Oncol; 2021 Sep; 47(9):2295-2303. PubMed ID: 33640171 [TBL] [Abstract][Full Text] [Related]
15. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma. Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473 [TBL] [Abstract][Full Text] [Related]
16. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831 [TBL] [Abstract][Full Text] [Related]
17. Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone. Achiam MP; Jensen LB; Larsson H; Jensen LS; Larsen AC; Holm J; Svendsen LB Scand J Surg; 2016 Mar; 105(1):22-8. PubMed ID: 25794689 [TBL] [Abstract][Full Text] [Related]
18. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer. Kudou K; Saeki H; Nakashima Y; Edahiro K; Korehisa S; Taniguchi D; Tsutsumi R; Nishimura S; Nakaji Y; Akiyama S; Tajiri H; Nakanishi R; Kurashige J; Sugiyama M; Oki E; Maehara Y Ann Surg Oncol; 2017 Jul; 24(7):1804-1810. PubMed ID: 28224363 [TBL] [Abstract][Full Text] [Related]
20. Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer. Nakashima Y; Saeki H; Hu Q; Tsuda Y; Zaitsu Y; Hisamatsu Y; Ando K; Kimura Y; Oki E; Mori M Ann Surg Oncol; 2020 Feb; 27(2):492-498. PubMed ID: 31549319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]